---
title: "GZYK issued a profit warning, expecting a net loss of 120 million to 180 million yuan for the fiscal year 2024"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/226179092.md"
description: "According to the announcement from GZYK, the company expects a net loss attributable to shareholders of the listed company of between 120 million yuan and 180 million yuan for the fiscal year 2024"
datetime: "2025-01-24T14:44:03.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/226179092.md)
  - [en](https://longbridge.com/en/news/226179092.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/226179092.md)
generator: "portal-rs"
---

# GZYK issued a profit warning, expecting a net loss of 120 million to 180 million yuan for the fiscal year 2024

According to the Zhitong Finance APP, GZYK (002524.SZ) announced that the company expects a net loss attributable to shareholders of the listed company of between 120 million yuan and 180 million yuan for the year 2024

### Related Stocks

- [002524.CN](https://longbridge.com/en/quote/002524.CN.md)

## Related News & Research

- [Grown Rogue outlines planned acquisition of PharmaCann New York cannabis license assets](https://longbridge.com/en/news/296775302.md)
- [08:13 ETAirworthy.com Releases 2026 State of General Aviation Parts Report](https://longbridge.com/en/news/296702598.md)
- [Predict signs Italy healthcare distribution deal for Robocore’s “temi” service robots](https://longbridge.com/en/news/296769892.md)
- [09:02 ETIMAGE Skincare Expands Its GLP-1-Targeted Skincare Innovation with New VOL.U.LIFT™ BODY Sculpt + Firm Treatment Complex](https://longbridge.com/en/news/296792631.md)
- [13:49 ETVascarta Outlines Proposed Mechanistic Link Between VAS-101's (Vasceptor®) Vascular and Red Blood Cell Effects in Sickle Cell Disease](https://longbridge.com/en/news/296524035.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**